Year: 2020

FREMONT, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) — Aehr Test Systems (NASDAQ: AEHR), a worldwide supplier of semiconductor test and reliability qualification equipment, today announced that it will report financial results for its second quarter of fiscal 2021 ended November 30, 2020 on Thursday, January 7, 2021 following the close of the market. The Company will host a conference call and webcast at 5:00 p.m. Eastern time to discuss the results.About Aehr Test SystemsHeadquartered in Fremont, California, Aehr Test Systems is a worldwide provider of test systems for burning-in and testing logic, optical and memory integrated circuits and has installed over 2,500 systems worldwide. Increased quality and reliability needs of the Automotive and Mobility integrated circuit markets are driving additional test requirements, incremental...

PLANO, Texas, Dec. 29, 2020 (GLOBE NEWSWIRE) — Denbury Inc. (NYSE: DEN) (“Denbury” or the “Company”) today announced that it has entered into an agreement with a subsidiary of Devon Energy Corporation to acquire a nearly 100% working interest (approximately 83% net revenue interest) in the Big Sand Draw and Beaver Creek oil fields located in Freemont County, Wyoming for a cash purchase price of $12 million. The purchase price includes associated surface facilities and the 46-mile CO2 transportation pipeline to the acquired fields.Net production from the acquired fields was approximately 2,800 barrels of oil equivalent (“BOE”) per day for the third quarter of 2020, of which approximately 85% was oil production. Based on December 1, 2020 oil and natural gas futures strip prices, net proved reserves for the acquired fields, which are...

TORONTO, Dec. 29, 2020 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (the “Company”) (CSE: BNKR) announces that on December 28, 2020, the United States Securities and Exchange Commission (“SEC”) declared effective the Company’s registration statement on Form S-1 (the “Registration Statement”) relating to resale by certain securityholders of the Company named in the Registration Statement of up to 166,114,748 common shares in the capital the Company previously issued by the Company and issuable by the Company upon the exercise of Common Share purchase warrants previously issued by the Company (the Common Shares so previously issued and issuable and qualified by the Registration Statement, the “Securities”).Concurrent with this declaration, the Company is pleased to announce that early-stage strategic investors have entered into voluntary...

DLR Kredit har fastsat kuponrenten for perioden 4. januar 2021 til 5. april 2021 på følgende variabelt forrentede obligationer:Senior Non-Preferred Note (SNP):ISIN-kode:          DK0006346036   SNP July 2021    0,4700 %Senior Non-Preferred Note (SNP):ISIN-kode:          DK0006348248   SNP July 2023    0,9200 %DLR Kredit har også fastsat kuponrenten for perioden 1. januar 2021 til 31. marts 2021 på følgende variabelt forrentede obligation:Senior Non-Preferred Note (SNP):ISIN-kode:          DK0006352273   SNP July 2024    0,6200 %Eventuelle spørgsmål kan rettes til Fonds og Funding på 33 42 07 37.Med venlig hilsenDLR Kredit A/SAttachmentRentefix20201229_DLR_SNP

TORONTO, Dec. 29, 2020 (GLOBE NEWSWIRE) — Routemaster Capital Inc. (the “Company” or “Routemaster”) (TSXV: RM) is pleased to announce it has led an investment of $100,000 in Luxor Technology Corporation (“Luxor”), the first institutional hashrate marketplace.As part of the deal, Routemaster has the right to invest an additional $200,000 into Luxor. Luxor intends to use the capital provided to make several key engineering hires to strengthen its development efforts of the hashrate marketplace. Luxor has so far helped miners mine over $45mm in cryptocurrency, supports over 28,000 miners globally, and ranks amongst the largest mining pools in the world according to the company. With its Seed round, Luxor will further build out its proof-of-work infrastructure.“The benefits of a hashrate marketplace are better transparency and the ability...

● Patent supporting Autosomal Dominant PolycysticKidney Disease Granted – XRx-008 Program ●CALGARY, Alberta, Dec. 29, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce receipt of notification that the patent “Formulations of Xanthine Oxidase Inhibitors” will be granted by the European Patent Office. The patent covers compositions and methods of using XORTX’s proprietary formulations of xanthine oxidase for, renal and other diseases where aberrant purine metabolism has been implicated in disease progression.Dr. Allen Davidoff, CEO of XORTX stated, “This newly granted patent, covers compositions of formulations key to XORTX’s platform technology...

Expands OVAL Phase 3 Potential Registration Study of VB-111 for the Treatment of Platinum-Resistant Ovarian Cancer into Europe TEL AVIV, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) today announced the expansion of its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer into Europe, where the first patient has now been enrolled. The study continues to actively recruit patients in the U.S. and Israel, with over 200 patients enrolled to date.“VB-111 is our proprietary anti-cancer gene therapy product candidate that has shown overall survival benefit across multiple tumor types,” said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. “We are pleased to expand the OVAL potential registration study of VB-111 in patients...

HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today it has entered into a collaboration agreement with Mexican pharmaceutical company Innovare R&D to expand its ongoing clinical program of PLX cells in the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 in Mexico. The Phase II study in Mexico is subject to the approval of local authorities, with the goal of being conducted under the U.S. Food and Drug Administration (FDA) cleared protocol.In accordance with the agreement, Innovare will open clinical sites and enroll patients for the proposed clinical study in Mexico. Innovare will fund the study in Mexico and will purchase...

LA JOLLA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis (progressive MS).Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039.  The allowed claims cover a method of (i) alleviating the negative effects of progressive multiple sclerosis, (ii) treating progressive multiple sclerosis, or (iii) slowing the progression of progressive multiple sclerosis by administering...